News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Clene Inc. announces positive results from CNM-Au8 results from MS trial

Clene Inc

Clene Inc (NASDAQ:CLNN) CEO Rob Etherington joined Steve Darling from Proactive to share news regarding the latest findings from the long-term open-label extension (LTE) of the VISIONARY-MS trial. This trial focuses on participants with stable relapsing multiple sclerosis (MS) and represents nearly three years of follow-up research. Following the conclusion of the double-blind period of the trial, participants were given the opportunity to continue with CNM-Au8® treatment at a dose of 30mg for an additional 96 weeks during the LTE phase. The analysis encompassed the modified intent-to-treat population, which included all study participants with valid clinical data. Etherington highlighted the key finding that long-term CNM-Au8 treatment showcased improvements in vision, as measured by low contrast visual acuity, an essential assessment of visual function in individuals living with multiple sclerosis. Remarkably, these improvements in vision persisted for 35 months from randomization, demonstrating the sustained efficacy of CNM-Au8 over an extended period. Moreover, the data revealed consistent and robust overall enhancements not only in vision but also in cognition among participants treated with CNM-Au8 for nearly three years from randomization. These results are particularly noteworthy for their potential to positively impact disease progression and potentially reverse established disability, representing a significant therapeutic breakthrough for patients with MS. Full clinical results from the long-term open-label extension will be officially presented at the ninth annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum, scheduled to take place from February 29 to March 2, 2024, in West Palm Beach, Florida. Clene's commitment to advancing treatments for multiple sclerosis is evident in these promising results, and their ongoing research holds great promise for enhancing the quality of life for individuals affected by this condition. The potential to offer effective long-term solutions and improve both vision and cognitive function is a significant step forward in the battle against multiple sclerosis. Contact Details Proactive Canada Proactive Canada +1 604-688-8158 action@proactiveinvestors.com

February 05, 2024 02:30 PM Eastern Standard Time

Video
Article thumbnail News Release

LungLife AI announces success in Validation of LungLB in multi-site, prospective clinical study

LungLife AI Inc

LungLife AI CEO Dr. Paul Pagano joined Steve Darling from Proactive to discussed the groundbreaking lung cancer detection technology developed by the company. LungLife AI is dedicated to addressing the critical issue of early detection in lung cancer, which remains the leading cause of cancer-related deaths. Dr. Pagano highlighted the sobering statistic that 80% of lung cancer cases are detected too late, contributing to the high mortality rate associated with this disease. The company's lung lb test, which has recently undergone successful validation, is poised to revolutionize the early detection of lung cancer by addressing the challenge of evaluating small nodules under 15 millimetres in size. Early intervention is crucial in improving patient outcomes, and the lung lb test is designed to meet this unmet need. Physicians have expressed excitement about the potential of this test to transform the landscape of lung cancer detection. Unlike existing methods, the lung lb test takes a unique approach by examining circulating genetically abnormal cells in the blood. This innovative approach offers a complementary and highly sensitive means of detecting lung cancer, enhancing the chances of early intervention and improved patient prognosis. Dr. Pagano discussed the competitive landscape, emphasizing LungLife AI's patented methods and proprietary technologies that set their approach apart in the field of lung cancer detection. Looking ahead, LungLife AI plans a methodical introduction of the lung lb test through an early access program, ensuring a seamless transition into healthcare settings. The next six to twelve months will involve a commercial proof of concept, with the company collaborating with hospital sites and working towards securing coverage from insurance providers. The potential life-saving impact of LungLife AI's technology and their strategic approach to making it accessible to patients and healthcare providers mark a significant contribution to advancing the field of lung cancer detection. The company's dedication to improving early detection rates and ultimately reducing the mortality associated with this devastating disease underscores their commitment to patient care and well-being. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

February 05, 2024 02:25 PM Eastern Standard Time

Video
Article thumbnail News Release

Flora Growth Corp's CEO Reveals Record-Breaking Financials and Exciting 2024 Plans

Flora Growth Corp

Flora Growth CEO Clifford Starke joined Steve Darling from Proactive to share exciting news about the company's remarkable financial performance and its strategic plans for the future. Flora Growth is a diversified company with three main pillars, and it recently reported its best-ever financial results. Starke highlighted Flora's three core pillars, Vessel which is a rapidly growing brand with widespread distribution, the CBD Gummy Division, and Fatima a pharmaceutical company based in South Germany. The company recently went under strategic restructuring, which included the sale of an unprofitable Colombian entity and streamlining its team, which led to a net income of $1.1 million in the last quarter. The success of the last quarter is attributed to these strategic decisions, setting the stage for a promising 2024. Looking ahead, Flora Growth plans to enter the rapidly growing US beverage market by launching a product called Mellow in Q1. Leveraging its strong distribution network, the company aims to capitalize on the untapped potential in the beverage segment. Starke emphasized the importance of continuous product innovation, hinting at upcoming releases in 2024 that will compete with established brands in the dry herb space. As Flora Growth anticipates a record-breaking year, Starke highlighted their commitment to product innovation and strategic expansion, positioning the company as one to watch in the cannabis industry. Contact Details Proactive United States Proactive United States +1 347-449-0879 action@proactiveinvestors.com

February 05, 2024 01:03 PM Eastern Standard Time

Video
Article thumbnail News Release

22nd Century Group CEO Larry Firestone: Transforming Tobacco Industry with FDA-Approved VLN Brand

22nd Century Group Inc

22nd Century Group new CEO Larry Firestone joined Steve Darling from Proactive to discuss his role and the company's strategic direction. 22nd Century Group is an agricultural biotech firm specializing in tobacco harm reduction and developing low-nicotine content plants for cigarettes. Notably, the company received FDA authorization for modified risk tobacco products in December 2021, with its flagship brand, VLN (Very Low Nicotine), aimed at addressing smoking-related health issues. Firestone emphasized the strategic shift the company is undergoing, which includes streamlining operations, divesting non-core assets such as the hemp cannabis business, and refocusing solely on the tobacco sector. The company's primary goal for 2024 is achieving financial self-sustainability, with a focus on cost optimization, gross margin improvement, and streamlining the overhead structure. 22nd Century Group is also committed to expanding its presence in established markets, particularly in the United States, and delivering its core products. Firestone's leadership will play a crucial role in guiding the company through these transformative changes and positioning it for growth and success in the coming years. This strategic shift and renewed focus on tobacco harm reduction reflect 22nd Century Group's commitment to addressing health-related issues associated with smoking and its determination to make a positive impact in the tobacco industry. Contact Details Proactive United States Proactive United States +1 347-449-0879 action@proactiveinvestors.com

February 05, 2024 07:29 AM Eastern Standard Time

Video
Article thumbnail News Release

2 Million Cancer Diagnoses And 600,000 Cancer Deaths Expected In 2024 – Prevention Is Key To Treatment, And Mainz Biomed Is Leading The Charge

Benzinga

By Faith Ashmore, Benzinga The global population is experiencing a scary increase in colorectal cancer, especially among young people. Colorectal cancer (CRC) diagnoses have been steadily rising since the 1990s; in 1995 the proportion of these cancer cases in adults younger than 55 was 11%, and in 2019, the number was 20%. It is recommended that adults start screening for colorectal cancer at age 45 but with the increase in prevalence, the value of early detection cannot be understated. While doctors still aren’t sure of the reason behind this increase, they are urging the public to take these numbers seriously and embrace preventative measures for early detection. Companies like Mainz Biomed (NASDAQ: MYNZ), a company that specializes in developing molecular genetic diagnostic solutions for life-threatening conditions, are leading the charge in helping make that happen. This company has created ColoAlert®, an innovative product that addresses the need for easier and more accessible cancer screenings for quick detection and treatment of colorectal cancer. The non-invasive and user-friendly test aims to make colorectal cancer screening fast, simple and precise. Once launched in the U.S. Mainz Biomed's ColoAlert will compete with Cologuard from Exact Sciences Corporation (NASDAQ: EXAS), a well-established company that commands a market cap of over $10 billion. The key difference between Cologuard and ColoAlert is that ColoAlert requires far less stool collection than its competitor, a testament to ColoAlert’s technology. This not only increases convenience for the patient but also cuts down on shipping costs and lab time. The only other detection model outside of a traditional colonoscopy is a blood-stool test; however, these tests can only detect cancer, not pre-cancerous polyps. Mainz Biomed has partnered with Liquid Biosciences to ensure its cutting-edge products are top-of-the-line. Recently, Mainz Biomed conducted a multi-center international clinical trial in Germany and Norway to evaluate the effectiveness of incorporating mRNA biomarkers into ColoAlert®. The study yielded impressive findings, demonstrating a high sensitivity of 94.4% and specificity of 97.5% for detecting CRC. Additionally, the screening test showed a sensitivity of 80% and specificity of 95.2% in detecting precursor lesions, including advanced adenomas that may develop into CRC. In other words, ColoAlert is designed to detect pre-cancerous polyps as well as identify individuals who have colorectal cancer. The CDC reports that colorectal cancer is the second most fatal cancer in the United States and Europe. However, it is also the most preventable, with early detection leading to survival rates above 90%. ColoAlert can be instrumental in preventive care for colorectal cancer. The company reports it has experienced success in Germany, where the product is available through labs, industry partnerships and online for purchase. In 2024, Mainz Biomed is looking to replicate this success in the U.S. and is planning to launch a pivotal trial, seeking FDA approval for its product. If successful, the company will look to partner with a network of labs across the country to increase accessibility to its product with the hope that more Americans will be able to detect pre-cancerous polyps before it is too late. With the American Cancer Society predicting over 600,000 cancer deaths and the equivalent of 5,000 cancer diagnoses each day in 2024, prevention is key to treatment. The preventive healthcare market has gotten a lot of attention in recent years, and it is expected to reach $415 billion by 2031 with a CAGR of 9.7% from 2024 to 2031. Mainz Biomed’s ColoAlert is a great example of the power of technology that can screen for pre-cancerous markers. Mainz Biomed's dedication to pushing the limits of diagnostic technology, enhancing accessibility and its growth trajectory potentially establish it as a formidable presence in the industry, setting it apart from its competitors. Featured photo by Artur Tumasjan on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 02, 2024 08:35 AM Eastern Standard Time

Image
Article thumbnail News Release

World’s largest radiology AI marketplace CARPL raises $6m to accelerate the adoption of AI in clinical workflows

CARPL

As people live longer and as emphasis on early detection of disease increases, there is a mounting burden on the healthcare services industry globally. This is being especially felt in radiology teams who are witnessing an acute shortage of radiologists. Currently, there are over 200 companies building applications using AI to automate parts of the radiologists’ work to bridge this talent gap. Today CARPL, an enterprise imaging AI marketplace platform, is announcing a $6m funding round to enable healthcare providers to access, assess and integrate these radiology AI applications into their clinical workflows through a single user-interface, single data channel and single procurement system. The seed funding round was led by Stellaris Venture Partners, a leading enterprise software investor, with participation from strategic angel investors* from Novo Holdings, Leapfrog PE, Bain & Co, Boston Consulting Group, UnitedHealth Group among others. CARPL will use the fresh funds to expand the team in North America and continue to build its tech stack. With more than 700 US-FDA approved AI applications, healthcare providers grapple with navigating the complex landscape of niche AI solutions. The daunting task involves determining the best AI solution for them and their patients, then seamlessly integrating it in the radiologists' workflows. This complexity has resulted in the sluggish pace of AI adoption in healthcare. A recent joint statement by the world’s top radiology associations also brings to light the importance of validation, deployment and monitoring of AI while being used in clinical practice. CARPL’s technology platform addresses this need using its proprietary DEV-D framework allowing healthcare providers to first Discover (D), Explore (E) and Validate (V) AI applications from CARPL’s AI marketplace, and subsequently Deploy (D) the most appropriate application across their clinical workflows. CARPL stands out as the only platform in the market with deep AI validation and monitoring capabilities, thereby ensuring safe and seamless AI deployment while upholding patient-centricity at its core. Additionally, CARPL’s universal AI viewer serves as a single user interface for radiologists, enabling them to accept, reject or refine AI outputs, which can subsequently be used to improve the performance of the AI itself. Operational since 2021, CARPL was founded by Vidur Mahajan, a physician with an MBA from the Wharton School of Business who has spent more than 12 years in the diagnostics industry. CARPL’s leadership comprises Dr Vasanth Venugopal as Chief Medical Officer, Rohit Takhar as CTO and most recently Dhruv Sahai as COO. CARPL has also ramped up its advisory team with the appointment of Dr Vijay Rao, SVP of Enterprise Imaging at Jefferson Health and a past-President of the Radiology Society of North America. “Over the past two years, we have onboarded more than 50 AI developers having 100+ AI applications, which made us the largest AI marketplace in terms of number of AI applications offered to customers. We are proud that some of the largest healthcare enterprises in the world have vetted our technology and trust us to be their partner in their AI and automation journeys.” said Dr Vidur Mahajan, CEO of CARPL. Drawing parallels with the lab medicine industry, Vidur Mahajan added: “We are democratizing radiology in the same way that automation and robotics revolutionized lab medicine, where a single pathologist signs out thousands of tests each day. We envision a future where CARPL creates ‘super-radiologists’ - AI-enabled radiologists who are ten times more productive than traditional radiologists.” Vidur Mahajan brings deep domain expertise having previously grown revenue 10x to $20m in 10 years at his family business Mahajan Imaging, a leading radiology service provider. He conceptualized CARPL under the guidance of his father Dr Harsh Mahajan, a pioneer in radiology, while working on validation and deployment of AI at Mahajan Imaging. CARPL comprises a multidisciplinary team with clinicians, scientists, engineers and business experts, all working towards the singular goal of driving exponential health outcomes using the encapsulated value of the entire AI ecosystem with the ultimate aim of ensuring access of quality diagnostics to patients. CARPL has more than 120 papers and conference presentations to its credit, and has coined some seminal concepts in clinical AI such as algorithmic audits, clinical explainability failure and unboxing AI. CARPL’s technology platform is used by the world’s top healthcare organizations like the Singapore Government, Massachusetts General Hospital (Boston), Radiology Partners (Los Angeles), University Hospitals (Cleveland), I-MED Radiology (Australia), Albert Einstein Hospital (São Paulo), Clinton Health Access Initiative, to name a few. CARPL is also creating impact in the public health space by working with the Government of India to enable large scale Tuberculosis Screening Programmes in the most remote regions of the country. As the global disease burden increases, owing to aging populations, early detection of disease and an increase in chronic/lifestyle diseases, the need for radiology services will increase, which increases the need for AI-assistance and automation in the delivery of these services. The global healthcare AI market is expected to cross $170 billion by 2029, of which almost $20 billion will be in the domain of radiology. Today, of the about 700 AI-based applications which are approved by the US-FDA, 80% are related to radiology. This number is expected to grow exponentially as access to training data and computation power becomes cheaper and easier to access. Alok Goyal, Partner at Stellaris Venture Partners commented: “The volume of imaging scans show a steady 9% year-on-year growth, outpacing the growth in the number of radiologists at a mere 1.8%. Bridging this demand gap is a crucial challenge for healthcare providers, and we believe AI will be the key. CARPL's integrated platform, designed for testing, deploying, and monitoring radiology AI applications, is poised to empower healthcare providers by seamlessly integrating AI into their clinical workflows. We are thrilled to join forces with Vidur and his team on this transformative journey.” As it becomes easier to build AI, the number and nature of AI applications used by doctors to deliver healthcare will increase exponentially. A platform approach that builds on connecting these AI developers to healthcare providers is the only way to exponentially improve the access, affordability and quality of care delivered today. CARPL is a new layer in the healthcare CIO’s stack that enables seamless access to the entire AI and analytics ecosystem through a single integrated platform. About CARPL CARPL is democratizing access to high quality healthcare by connecting AI applications and healthcare providers, exponentially improving the access, affordability and quality of medical care. CARPL enterprise imaging AI platform provides a single user-interface, data channel and procurement system for healthcare providers to access, assess, integrate and buy radiology AI applications in a safe and seamless manner. CARPL was incubated at Mahajan Imaging & Labs, India’s largest radiology service provider, as its technology division focused on building scalable clinical tools for AI validation, deployment and monitoring, under the guidance of Dr Harsh Mahajan, a pioneer in the field of radiology. For more information please visit https://carpl.ai About Stellaris Venture Partners Stellaris is an early-stage tech-focused VC firm that partners with fearless founders who dream big, think differently, and have an unstoppable desire to challenge the status quo. The fund works with these teams at nascent stages to help transform their ideas into resilient businesses. Stellaris does so with a team of seasoned, diverse operators and entrepreneurs who bring significant experience in building businesses and by providing access to some of the most successful founders and professionals. Since its inception in 2017, Stellaris has backed many market leaders such as Mamaearth, Whatfix, Propelld, Turno, Rigi, and others. For more information on Stellaris Venture Partners, visit https://www.stellarisvp.com Contact Details CARPL Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://carpl.ai/

February 01, 2024 09:00 AM Eastern Standard Time

Image
Article thumbnail News Release

The Best AI Girl Generator Apps You Must Try 2024

Summit Ventures BV

In today's technologically driven world, AI girl generator apps have gained immense popularity for their ability to create virtual AI companions. With a plethora of options available, we've curated a list of top-notch AI girl generator tools that you should explore in 2024. These applications offer innovative AI girl generation capabilities, providing unique and engaging experiences. Table of Featured AI Girl Generators 1. Introduction to AI Generated Girls 2. Featured AI Girl Generator Tools 2.1 GPTGirlfriend.online 2.2 GlamGirls.ai 2.3 ChaiApp.pro 2.4 AI-Girlfriend.co 2.5 AI-Companion.co 3. Frequently Asked Questions 4. Conclusion Top Five AI Girl Generator Apps The world of AI girl generators has seen significant growth, offering a variety of engaging options. While each application brings its unique features to the table, GPTGirlfriend.online stands out with its exceptionally engaging interactions and a wide range of capabilities. Girlfriend GPT: Your Gateway to AI Generated Girls Girlfriend GPT is an innovative AI-powered tool that brings your favorite AI girl characters to life, offering interactive experiences. This platform provides a wide array of activities, enabling you to create a virtual space for engaging conversations with your AI girl companion. Moreover, GPTGirlfriend.online offers unrestricted content for a diverse experience. Key Features: Empowers you to create your personalized AI girl companion. Allows unrestricted interactions and conversations. Offers affordable premium and deluxe subscription plans. Resumes conversations with long-term memory. Glam Girls AI: Generate your AI Girl in Seconds Glam Girls is renowned for having the best AI generated girls in the space. This platform is designed for those interested in crafting glamorous AI characters. Whether you're looking for AI girls with a sense of style or unique personalities, GlamGirls.ai has you covered. Key Features: Multiple scenarios for AI girl generation. Customizable interface to align with your preferences. Accommodates various interests and preferences in AI girl characters. Chai App: Create AI Girls for NSFW AI Images Chai App offers an intuitive platform for generating AI girls and companions, particularly suited for NSFW AI image generation. This application excels in providing realistic AI chatbot interactions and customization options for your AI girl companions. Key Features: Intuitive navigation for an immersive experience. Realistic chatbot interactions. Allows customization of AI girl companions. Features advanced capabilities for generating AI girls. AI Girlfriend: Personalized AI Girlfriends for Engaging Conversations AI-Girlfriend.co is the perfect choice for those seeking personalized AI girlfriends. This platform allows you to tailor your AI girlfriend according to your preferences. AI-Girlfriend.co creates engaging and realistic interactions with your ideal AI girlfriend character. Key Features: Provides realistic AI companion interactions with varied emotions and backgrounds. Abundance of features available for diverse AI girlfriend interactions. Offers budget-friendly pricing for personalized AI girlfriends. AI Companion: Engage with AI waifus and husbands AI-Companion.co is known for its wide range of character options in the AI girl generator domain. This versatile platform accommodates various conversations and interactions with AI chatbots, offering personalized experiences. Key Features: Support for multiple languages, enhancing accessibility. Personalization options to tailor the chatbot according to individual preferences. Broad spectrum of interests and character types for diverse user needs. Frequently Asked Questions Q: What is an AI girl generator? A: An AI girl generator is a software application that uses artificial intelligence to create virtual AI girl characters for various purposes, such as entertainment, interaction, or chatbot companionship. Q: How do AI girl generators work? A: AI girl generators work by utilizing advanced algorithms and machine learning techniques to generate AI girl characters with customizable traits, personalities, and conversation capabilities. Q: Can a AI girl generator be used for NSFW content? A: Some AI generated girls are designed to cater to NSFW (Not Safe For Work) content, offering options for more mature and adult-themed interactions. However, not all AI girl generator apps support explicit content. Q: Can I customize AI girl characters generated by these tools? A: Yes, most AI girl generator apps allow users to customize AI girl characters by selecting specific traits, appearances, and personalities to create personalized virtual companions. Q: Are there age restrictions for using AI girl generators? A: Yes, to use AI girl generators, users typically need to be at least 18 years old, as these tools may generate content that is intended for adults. Conclusion In the realm of technology, AI generated girls offer a gateway to interactive virtual companionship. These tools have transformed how we connect with AI characters, providing endless entertainment and personal interactions. Whether you seek customizable AI girls, engaging AI girlfriends, or glamorous AI characters, these apps cater to diverse preferences. They bridge the virtual and real worlds, offering a glimpse into the potential of AI companions. This guide has highlighted top AI girl generator apps in 2024, each with unique features. Some may include NSFW content, so choose accordingly. AI girlfriend apps pioneer technological innovation, enabling users to create, personalize, and interact with AI characters. Explore these apps for a distinctive experience in the world of AI companionship. Unlock the potential of AI girl generators today. GPTGirlfriend.online is the most advanced AI companion subscription service with a community of more than 1,000,000 Monthly Active Users. With more than 25,000 characters, it has transformed how people interact with and experience AI. Please refer to our detailed Terms of Use and Community Guidelines for comprehensive information on usage, safety, and ethical considerations on GPTGirlfriend.online Contact Details GPTGirlfriend Business hello@enias.io Company Website https://www.gptgirlfriend.online

February 01, 2024 08:30 AM Eastern Standard Time

Image
Article thumbnail News Release

First Patient Dosed In Phase 2 Study Of Elicio Therapeutics’ ELI-002 7P

Benzinga

By Jeremy Golden, Benzinga A phase 2 trial by a clinical-stage biotechnology company is kicking into full gear. As part of its randomized phase 2 AMPLIFY-7P study of ELI-002 7P as an adjuvant monotherapy in Kirsten Rat Sarcoma (KRAS) mutated pancreatic ductal adenocarcinoma (PDAC), Elicio Therapeutics Inc. (NYSE: ELTX) has dosed the first patient at Northwell Health Cancer Institute and the Feinstein Institutes for Medical Research in New York. ELI-002 7P is an investigational therapeutic cancer vaccine developed with Elicio’s proprietary lymph node-targeting Amphiphile (AMP) technology to treat cancers driven by seven common mutations in KRAS: G12D, G12R, G12V, G12A, G12C, G12S and G13D. Those are present in 25% of all solid tumor cancers and 88% of PDAC patients. This is in contrast to other KRAS-targeted therapeutics in development, particularly small molecule KRAS inhibitors. Those target fewer mutations – potentially limiting the number of patients who can be treated – while also limiting the duration of benefit due to the development of escape mutants. The AMPLIFY-7P study builds on preliminary positive findings from the 2-peptide formulation of ELI-002 published in Nature Medicine. That data demonstrated tumor biomarker reduction, with strong T cell responses that correlated with reduced risk of relapse and death. Christopher Haqq, M.D., Ph.D., Elicio’s Executive Vice President, Head of Research and Development and Chief Medical Officer, anticipates results from this study will yield definitive data to support clinical efficacy assessment. Initial interim data on ELI-002 7P monotherapy from phase 1A arm will be shared in the first half of 2024, the company said. “Approximately 90% of pancreatic cancers are positive for KRAS mutations, with only rare G12C mutations, about 1%, amenable to small molecule treatment,” Haqq said. “ELI-002 represents a cancer vaccine approach that could potentially address the much broader spectrum of pancreatic cancer KRAS mutations.” In January, Elicio presented a Trial in Progress poster on the design of the AMPLIFY-7P trial at the ASCO Gastrointestinal Cancers Symposium in San Francisco, California. The poster describes the phase 1 and randomized phase 2 study of ELI-002 7P, an investigational therapeutic cancer vaccine administered as an adjuvant monotherapy treatment for patients with KRAS-mutated pancreatic ductal adenocarcinoma (PDAC). “ELI-002 is an off-the-shelf cancer vaccine candidate developed with our proprietary Amphiphile (“AMP”) platform which provides a new ability to deliver these treatments effectively to the ‘command center’ of the immune response – the lymph nodes – where tumor-fighting T cells are generated and equipped,” Haqq said. “We are progressing our AMP-powered, lymph node-targeted cancer vaccine, ELI-002 7P, as a monotherapy in an adjuvant setting for patients with pancreatic cancer, and recently dosed the first patient in the randomized Phase 2 cohort.” “Patients with RAS mutated pancreatic cancers who have positive circulating tumor DNA post-surgery are often quick to relapse,” added Zev A. Wainberg, M.D., Professor of Medicine, University of California, Los Angeles (UCLA), Co-Director, the UCLA GI Oncology Program. “Our current standard of care for these patients is observation — there are no treatments given during this ‘wait and see’ observation window before relapse. As we progress to Phase 2 of the study, we seek to compare ELI-002 7P to our current standard of care to further evaluate its antitumor activity and clinical benefit in the adjuvant setting as well as with bulkier cancer treated at the time of relapse in crossover patients with mKRAS-driven pancreatic cancer.” Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 01, 2024 08:15 AM Eastern Standard Time

Article thumbnail News Release

University of Dayton Law School Leads the Way in Contract Excellence with the Adoption of the NCMA Contract Management Standard™

National Contract Management Association

The University of Dayton School of Law (UDSL) proudly announces its commitment to advancing education in Government Contracting & Procurement through the adoption of the National Contract Management Association's (NCMA) ANSI-approved Contract Management Standard™ (CMS™) and Contract Management Book of Knowledge ® (CMBOK ® ). The Master in the Study of Law (M.S.L.) in Government Contracting & Procurement program at UDSL is dedicated to providing students with the highest quality education and ensuring they are equipped with the knowledge and skills necessary for success in the ever-evolving profession of contract management. By incorporating the NCMA CMS™ and CMBOK ® into its program and course curricula, UDSL reaffirms its commitment to academic excellence and aligns with contract management best practices. Kraig Conrad, CEO of the National Contract Management Association, expressed enthusiasm about the partnership, stating, "We commend the University of Dayton School of Law for taking this progressive step for their program. This standard is a recognized benchmark in the profession, and its incorporation into UDSL's program reflects the university's dedication to providing students with a competitive edge in their careers." The NCMA CMS™ and CMBOK ® will serve as the foundation for UDSL's M.S.L. program, guiding the development of curriculum that addresses the dynamic and complex landscape of government contracting and procurement. This strategic adoption ensures that students receive comprehensive and up-to-date education and prepares them for success in the workforce. In response to the adoption, Sabra Tomb, UDSL’s Director of Training Programs and Strategic Business Development stated, "UDSL’s Government Contracting & Procurement Program is committed to delivering excellence in education and preparing our students to excel in their professional pursuits. The integration of the NCMA Contract Management Standard™ into our program is a testament to our dedication to providing a top-notch education that meets the needs of the industry and empowers our students for success." As UDSL continues to strengthen its position as a leader in legal education, this decision underscores its commitment to staying at the forefront of profession advancements and provide students with a competitive advantage in the job market. The National Contract Management Association (NCMA) – www.ncmahq.org – stands as the premier contract management organization whose mission is to collaborate towards a globally recognized contract management profession that strengthens its nexus with related acquisition communities. Serving approximately 20,000 members in both the public and private sectors, NCMA propels the growth, advancement, and impact of practitioners through a steadfast commitment to serve through the open exchange of ideas in neutral forums. The School of Law offers a fully online master's program in government contracting and procurement designed by seasoned industry and government experts. The program is designed for contract professionals; a law degree is not required. Courses are taught in real-time to encourage active learning and provide opportunities for live feedback and interaction between faculty and students. Each class meets once a week, scheduled for working professionals. Financial aid, military, and veteran benefits; and corporate and government tuition deferment, assistance and reimbursement options are available. For more visit: https://udayton.edu/law/. Contact Details National Contract Management Association Holly DeHesa +1 281-865-3296 holly.dehesa@ncmahq.org Company Website https://www.ncmahq.org

February 01, 2024 05:00 AM Eastern Standard Time

1 ... 2930313233 ... 221